Internal Medicine, Hematology & Oncology · Hot Springs, AR
NPI
1841277589
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
133 Harmony Park
Hot Springs, AR, 71913
Phone (501) 624-7700
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.9M
368,912 services
Medicare patients, 2024
1,257
Average age 76
Drug cost, 2024
$3.9M
2,241 prescriptions
Company payments, 2025
$2,553
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert T Muldoon was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 76,200 times for 68 patients. In total Robert T Muldoon billed 368,912 services in 193 codes, and Medicare paid $6.9M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-12-29.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 76,200 | 68 | $2.33 | $177K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 32,600 | 32 | $44.68 | $1.5M |
| J9299 Injection, nivolumab, 1 mg | Office | 30,685 | 19 | $24.60 | $755K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 18,300 | 164 | $0.10 | $1,864 |
| Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 16,080 | 24 | $0.37 | $5,972 |
| J0185 Injection, aprepitant, 1 mg | Office | 15,860 | 41 | $1.30 | $21K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 11,200 | 12 | $0.06 | $618 |
| J9267 Injection, paclitaxel, 1 mg | Office | 9,220 | 15 | $0.08 | $748 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 9,000 | 79 | $15.42 | $139K |
| J0897 Injection, denosumab, 1 mg | Office | 4,080 | 31 | $20.44 | $83K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 3,635 | 14 | $32.00 | $116K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,251 | 101 | $0.09 | $286 |
| 36415 Venipuncture Blood Collection | Office | 2,630 | 911 | $8.59 | $23K |
| 85025 Blood Count | Office | 2,431 | 855 | $7.59 | $18K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,810 | 61 | $0.71 | $1,281 |
By year: 2022 $4.5M for 348,574 services; 2023 $5.3M for 342,682 services; 2024 $6.9M for 368,912 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 2,630 | 911 | $8.59 | $23K |
| 85025 Blood Count | 2,431 | 855 | $7.59 | $18K |
| 85045 Blood Count | 60 | 54 | $3.87 | $232 |
| 81002 Clinical Chemistry | 38 | 35 | $3.41 | $130 |
Medicare prescription drug claims, 2024
In 2024, the drug Robert T Muldoon prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 126 prescriptions and refills. In total Robert T Muldoon wrote 2,241 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 126 | 126 | 39 | $3,541 |
| Anastrozole Generic | 119 | 223 | 31 | $1,265 |
| Ondansetron Odt Ondansetron | 105 | 105 | 63 | $1,171 |
| Prednisone Generic | 103 | 115 | 44 | $654 |
| Pantoprazole Sodium Generic | 93 | 112 | 22 | $529 |
| Levothyroxine Sodium Generic | 83 | 94 | 15 | $447 |
| Zarxio Filgrastim-Sndz | 75 | 76 | 16 | $134K |
| Letrozole Generic | 73 | 122 | 17 | $812 |
| Gabapentin Generic | 72 | 77 | 19 | $893 |
| Promethazine Hcl Generic | 55 | 57 | 34 | $369 |
| Eliquis Apixaban | 50 | 66 | 15 | $37K |
| Jakafi Ruxolitinib Phosphate | 49 | 49 | Under 11 | $681K |
| Citalopram Hbr Citalopram Hydrobromide | 45 | 50 | Under 11 | $76.22 |
| Tramadol Hcl Generic | 37 | 37 | 21 | $147 |
| Dexamethasone Generic | 36 | 40 | 16 | $258 |
Brand drugs: - claims; generic drugs: 1,723 claims; opioid claims: 229.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert T Muldoon $2,553 ($2,553 in general payments such as food, travel and fees) from 41 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $281.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 10 | $281 |
| Novartis Pharmaceuticals Corporation NVS | 21 | $252 |
| Pfizer Inc. PFE | 11 | $191 |
| Celgene Corporation BMY | 17 | $171 |
| Exelixis Inc. EXEL | 8 | $157 |
| Merck Sharp & Dohme LLC MRK | 9 | $149 |
| Janssen Biotech, Inc. JNJ | 8 | $136 |
| Daiichi Sankyo Inc. 4568.T | 6 | $131 |
| Eisai Inc. 4523.T | 5 | $86.65 |
| Incyte Corporation INCY | 3 | $69.17 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.